-
摘要: 常染色体显性多囊肾病(ADPKD)是一种常见的单基因遗传性肾病,可进展为终末期肾病(ESRD)。ADPKD患者常反复发生囊内感染,抗生素治疗所产生的耐药性问题日益突出,肾移植手术方式也需根据多囊肾的感染情况进行选择。本文从肾囊肿起源、囊肿的分类及囊液的来源、囊液内细菌类型及其耐药性、ADPKD患者囊内感染与肾移植治疗等方面进行综述,为ADPKD患者囊内感染的诊治提供参考。Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenic hereditary kidney disease, which can progress into end-stage renal disease (ESRD). Patients with ADPKD constantly suffer from recurrent intracapsular infection. The drug resistance caused by antibiotic treatment is becoming increasingly prominent. The pattern of renal transplantation should be selected according to the infection of polycystic kidney disease. In this article, the origin of renal cyst, classification and source of cystic fluid, type and drug resistance of bacteria in the cystic fluid, and intracapsular infection of patients with renal transplantation- associated ADPKD were reviewed, aiming to provide reference for the diagnosis and treatment of intracapsular infection of patients with ADPKD.
-
Key words:
- Polycystic kidney disease /
- Infection /
- Cyst /
- Cystic fluid /
- Bacteria /
- Antibiotic /
- End-stage renal disease (ESRD) /
- Drug resistance
-
[1] BERGMANN C, GUAY-WOODFORD LM, HARRIS PC, et al. Polycystic kidney disease[J]. Nat Rev Dis Primers, 2018, 4(1): 50. DOI: 10.1038/s41572-018-0047-y. [2] SAITO T, TANAKA Y, MORISHITA Y, et al. Proteomic analysis of AQP11-null kidney: proximal tubular type polycystic kidney disease[J]. Biochem Biophys Rep, 2017, 13: 17-21. DOI: 10.1016/j.bbrep.2017.11.003. [3] TAN AY, ZHANG T, MICHAEEL A, et al. Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease[J]. J Am Soc Nephrol, 2018, 29(8): 2139-2156. DOI: 10.1681/ASN.2017080878. [4] TSUKIYAMA T, KOBAYASHI K, NAKAYA M, et al. Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease[J]. Nat Commun, 2019, 10(1): 5517. DOI: 10.1038/s41467-019-13398-6. [5] KUNNEN SJ, MALAS TB, FORMICA C, et al. Comparative transcriptomics of shear stress treated PKD1-/- cells and pre-cystic kidneys reveals pathways involved in early polycystic kidney disease[J]. Biomed Pharmacother, 2018, 108: 1123-1134. DOI: 10.1016/j.biopha.2018.07.178. [6] DWIVEDI N, TAO S, JAMADAR A, et al. Epithelial vasopressin type-2 receptors regulate myofibroblasts by a YAP-CCN2-dependent mechanism in polycystic kidney disease[J]. J Am Soc Nephrol, 2020, 31(8): 1697-1710. DOI: 10.1681/ASN.2020020190. [7] PADOVANO V, PODRINI C, BOLETTA A, et al. Metabolism and mitochondria in polycystic kidney disease research and therapy[J]. Nat Rev Nephrol, 2018, 14(11): 678-687. DOI: 10.1038/s41581-018-0051-1. [8] REIF GA, WALLACE DP. ADPKD cell proliferation and Cl--dependent fluid secretion[J]. Methods Cell Biol, 2019, 153: 69-92. DOI: 10.1016/bs.mcb.2019.06.001. [9] YANDA MK, CHA B, CEBOTARU CV, et al. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease[J]. J Biol Chem, 2019, 294(45): 17090-17104. DOI: 10.1074/jbc.RA119.010320. [10] NANTAVISHIT J, CHATSUDTHIPONG V, SOODVILAI S. Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion[J]. Biochem Pharmacol, 2018, 154: 175-182. DOI: 10.1016/j.bcp.2018.05.005. [11] JANSSON K, VENUGOPAL J, SÁNCHEZ G, et al. Ouabain regulates CFTR-mediated anion secretion and Na, K-ATPase transport in ADPKD cells[J]. J Membr Biol, 2015, 248(6): 1145-1157. DOI: 10.1007/s00232-015-9832-7. [12] MALEKSHAHABI T, KHOSHDEL RAD N, SERRA AL, et al. Autosomal dominant polycystic kidney disease: disrupted pathways and potential therapeutic interventions[J]. J Cell Physiol, 2019, 234(8): 12451-12470. DOI: 10.1002/jcp.28094. [13] KENTER AT, VAN ROSSUM-FIKKERT SE, SALIH M, et al. Identifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease[J]. Am J Physiol Renal Physiol, 2019, 316(1): F204-F213. DOI: 10.1152/ajprenal.00470.2018. [14] LYU Z, MAO Z, LI Q, et al. PPARγ maintains the metabolic heterogeneity and homeostasis of renal tubules[J]. EBioMedicine, 2018, 38: 178-190. DOI: 10.1016/j.ebiom.2018.10.072. [15] LANKTREE MB, CHAPMAN AB. New treatment paradigms for ADPKD: moving towards precision medicine[J]. Nat Rev Nephrol, 2017, 13(12): 750-768. DOI: 10.1038/nrneph.2017.127. [16] HAMANOUE S, SUWABE T, UBARA Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: penetration of meropenem into infected cysts[J]. BMC Nephrol, 2018, 19(1): 272. DOI: 10.1186/s12882-018-1067-2. [17] LANTINGA MA, DE SÉVAUX RGL, GEVERS TJG, et al. Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver disease[J]. Neth J Med, 2018, 76(5): 226-234. http://www.researchgate.net/publication/326491551_Clinical_predictors_of_escalating_care_in_hepatic_and_renal_cyst_infection_in_autosomal_dominant_polycystic_kidney_and_liver_disease [18] GAO C, ZHANG L, ZHANG Y, et al. Insights into cellular and molecular basis for urinary tract infection in autosomal-dominant polycystic kidney disease[J]. Am J Physiol Renal Physiol, 2017, 313(5): F1077-F1083. DOI: 10.1152/ajprenal.00279.2017. [19] SUWABE T, ARAOKA H, UBARA Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics[J]. Eur J Clin Microbiol Infect Dis, 2015, 34(7): 1369-1379. DOI: 10.1007/s10096-015-2361-6. [20] YUAN X, LIU T, WU D, et al. Epidemiology, susceptibility, and risk factors for acquisition of MDR/XDR Gram-negative bacteria among kidney transplant recipients with urinary tract infections[J]. Infect Drug Resist, 2018, 11: 707-715. DOI: 10.2147/IDR.S163979. [21] LANTINGA MA, CASTELEIJN NF, GEUDENS A, et al. Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review[J]. Nephrol Dial Transplant, 2017, 32(1): 144-150. DOI: 10.1093/ndt/gfv452. [22] SUWABE T, UBARA Y, HAYAMI N, et al. Factors influencing cyst infection in autosomal dominant polycystic kidney disease[J]. Nephron, 2019, 141(2): 75-86. DOI: 10.1159/000493806. [23] OIKONOMOU KG, ALHADDAD A. Isolation rate and clinical significance of uropathogens in positive urine cultures of hemodialysis patients[J]. J Glob Infect Dis, 2017, 9(2): 56-59. DOI: 10.4103/0974-777X.204691. [24] CHOE HS, LEE SJ, CHO YH, et al. Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-year results of the Global Prevalence Study of Infections in Urology (GPIU)[J]. J Infect Chemother, 2018, 24(4): 278-283. DOI: 10.1016/j.jiac.2017.11.013. [25] TANDOGDU Z, CAI T, KOVES B, et al. Urinary tract infections in immunocompromised patients with diabetes, chronic kidney disease, and kidney transplant[J]. Eur Urol Focus, 2016, 2(4): 394-399. DOI: 10.1016/j.euf.2016.08.006. [26] JANEIRO D, PORTOLÉS J, TATO AM, et al. Peritoneal dialysis can be an option for dominant polycystic kidney disease: an observational study[J]. Perit Dial Int, 2015, 35(5): 530-536. DOI: 10.3747/pdi.2014.00029. [27] OH J, SHIN CI, KIM SY. Infected cyst in patients with autosomal dominant polycystic kidney disease: analysis of computed tomographic and ultrasonographic imaging features[J]. PLoS One, 2018, 13(12): e0207880. DOI: 10.1371/journal.pone.0207880. [28] IETTO G, RAVEGLIA V, ZANI E, et al. Pretransplant nephrectomy for large polycystic kidneys in ADPKD (autosomal dominant polycystic kidney disease) patients: is peritoneal dialysis recovery possible after surgery?[J]. Biomed Res Int, 2019: 7343182. DOI: 10.1155/2019/7343182. [29] VEROUX M, ZERBO D, PALMUCCI S, et al. Simultaneous nephrectomy and ipsilateral dual kidney transplantation in patients with autosomal polycystic kidney disease[J]. Transplantation, 2016, 100(1): e3-e4. DOI: 10.1097/TP.0000000000000982. [30] VEROUX M, GOZZO C, CORONA D, et al. Change in kidney volume after kidney transplantation in patients with autosomal polycystic kidney disease[J]. PLoS One, 2018, 13(12): e0209332. DOI: 10.1371/journal.pone.0209332. [31] PERICO N, CORTINOVIS M, REMUZZI G. Renal transplantation in autosomal dominant polycystic kidney disease (ADPKD)[J]. G Ital Nefrol, 2016, 33(5): gin/33.5.20. [32] ILLESY L, KOVÁCS DÁ, SZABÓ RP, et al. Autosomal dominant polycystic kidney disease transplant recipients after kidney transplantation: a single-center experience[J]. Transplant Proc, 2017, 49(7): 1522-1525. DOI: 10.1016/j.transproceed.2017.06.014. [33] MAXEINER A, BICHMANN A, OBERLÄNDER N, et al. Native nephrectomy before and after renal transplantation in patients with autosomal dominant polycystic kidney disease (ADPKD)[J]. J Clin Med, 2019, 8(10): 1622. DOI: 10.3390/jcm8101622.
点击查看大图
计量
- 文章访问数: 339
- HTML全文浏览量: 190
- PDF下载量: 49
- 被引次数: 0